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OBJECTIVE—Acylated ghrelin (AG) is a diabetogenic and
orexigenic gastric polypeptide. These properties are not shared
by the most abundant circulating form, which is unacylated
(UAG). An altered UAG/AG proﬁle together with an impairment
of circulating endothelial progenitor cell (EPC) bioavailability
were found in diabetes. Based on previous evidence for the
beneﬁcial cardiovascular effects of AG and UAG, we investigated
their potential to revert diabetes-associated defects.
RESEARCH DESIGN AND METHODS—Healthy human sub-
jects, individuals with type 2 diabetes, and ob/ob mice were AG or
UAG infused. EPC mobilization in patients and mice was evalu-
ated, and the underlying molecular mechanisms were investi-
gated in bone marrow stromal cells. Recovered EPCs were also
evaluated for the activity of senescence regulatory pathways and
for NADPH oxidase activation by knocking down p47
phox and
Rac1. Finally, UAG modulation of human EPC vasculogenic
potential was investigated in an in vivo mouse model.
RESULTS—Neither AG nor UAG had any effect in healthy
subjects. However, systemic administration of UAG, but not AG,
prevented diabetes-induced EPC damage by modulating the
NADPH oxidase regulatory protein Rac1 and improved the
vasculogenic potential both in individuals with type 2 diabetes
and in ob/ob mice. In addition, unlike AG, UAG facilitated the
recovery of bone marrow EPC mobilization. Crucial to EPC
mobilization by UAG was the rescue of endothelial NO synthase
(eNOS) phosphorylation by Akt, as UAG treatment was ineffec-
tive in eNOS knockout mice. Consistently, EPCs expressed
speciﬁc UAG-binding sites, not recognized by AG.
CONCLUSIONS—These data provide the rationale for clinical
applications of UAG in pathologic settings where AG fails.
Diabetes 59:1016–1025, 2010
G
hrelin is a 28–amino acid peptide that circulates
in both acylated (AG) and, more abundantly,
unacylated forms (UAG) (1). Historically, AG,
usually referred to as ghrelin, has been consid-
ered the only active form of the peptide. It recognizes the
Gq-coupled growth hormone secretagogue receptor type 1a,
denoted as GHS-R1a (2), mediating its growth hormone–
releasing properties as well as other signiﬁcant neuroendo-
crine actions (3). In contrast, UAG does not bind the GHS-
R1a and is devoid of growth hormone secretagogue activity
(3). Nevertheless, both AG and UAG share afﬁnity for com-
mon binding sites that mediate vascular activities in terms of
vasodilation and inhibition of cardiomyocyte and endothelial
cell apoptosis (3). Furthermore, UAG effects, different from
those elicited by AG, have also been demonstrated (4),
suggesting the existence of an additional unidentiﬁed recep-
tor for UAG.
Besides expression in several tissues (5), including the
cardiovascular system (6,7), ghrelin is produced mostly by
the stomach. In particular, in humans, AG reduces insulin
sensitivity and exerts orexigenic activity, whereas UAG
has opposite effects (8). Circulating total ghrelin levels are
negatively associated with BMI (9), and ghrelin secretion
is reduced in obese (10) and type 2 diabetic (11) individ-
uals, possibly as a compensatory mechanism protecting
against hyperglycemia. Interestingly, a relative excess
of AG compared with UAG has been reported in clinical
conditions marked by insulin resistance (12), raising the
possibility that the altered UAG/AG ratio could play a
role in the altered glucose metabolism and its ongoing
complications.
Among such complications, accelerated vascular dis-
ease is widely recognized as the major cause of disability
and death in individuals with type 2 diabetes. Endothelial
injury is thought to represent a crucial step in the initiation
and progression of atherosclerotic vascular disease in this
setting (13). Previous data support the central role of
advanced glycosylation end products (AGEs) (14) and of
NADPH oxidase–mediated reactive oxygen species (ROS)
production in impaired vascular remodeling associated
with diabetes (15). NADPH oxidase (Nox) consists of a
membrane-bound catalytic subunit and several cytosolic
regulatory subunits (p47
phox and p67
phox). Moreover, the
GTPase-bound Rac1 is required for the functional assem-
bly of the holoenzyme (15).
Vascular remodeling relies on resident endothelial cells
and on circulating endothelial progenitor cells (EPCs):
early circulating angiogenic cells (CACs) and late EPCs
(16,17). Although they share several common features,
they have distinct features with respect to morphology,
proliferative potential, and functional characteristics (18).
Compelling evidence indicates that changes in their num-
ber and functional activities are closely associated with
cardiovascular risk factor proﬁles (19,20), impacting on
their delivery to sites of ischemia where angiogenesis
might be required. Indeed, treatment with certain cyto-
kines to induce bone marrow mobilization of EPCs has
been shown to be cardioprotective (21). EPC mobilization
strictly depends on local secretion and activation of the
matrix metalloproteinase 9 (MMP9) in the hematopoietic
and stromal compartments of the bone marrow (22). In
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of the Kit ligand (mbKitL) into a soluble form (sKitL) that
promotes hematopoietic and endothelial progenitor cell
proliferation and facilitates their mobilization into the
circulation (22). Because an impairment of progenitor cell
mobilization has also been reported in mice lacking endo-
thelial NO synthase (eNOS) (23), eNOS may also be
involved in the control of progenitor cell delivery to sites
of neovascularization. Consistently, pathologic settings,
characterized by reduced systemic NO bioavailability, also
show defective EPC mobilization and compromised vas-
cular regenerative processes (24,25).
Based on previous evidence for cardiovascular protec-
tive effects of both AG and UAG, the aim of the present
study was to investigate the therapeutic potential of ghre-
lin isoforms in diabetes-associated vascular disease and
related mechanisms. Herein, we demonstrate that UAG,
but not AG, systemic administration protects diabetic
EPCs from senescence and restores their vasculogenic
potential by regulating the small GTPase Rac1 activity.
Finally, we show that UAG, unlike AG, rescues defective
EPC mobilization in individuals with type 2 diabetes, but
has no effect in healthy subjects.
RESEARCH DESIGN AND METHODS
Patients and control subjects. Blood was recovered from 14 individuals
with type 2 diabetes who arrived in our patient clinic (sex [M/F], 8/6; A1C, 8 
1.2%; age, 55.8  9.46 years; BMI, 28.1  3.22 kg/m
2; creatinine, 1.06  0.20
mg/dl; waist circumference, 98.8  8.02 cm; total cholesterol, 198  30 mmol/l;
HDL cholesterol, 48  12.98 mmol/l; LDL cholesterol, 115  38.94 mmol/l;
triglycerides, 159.5  55.23 mg/dl; fasting glucose, 125  18.03 mg/dl; no
retinopathy; hypertension in three patients; blood pressure, 142/89 mmHg;
cholesterol/apolipoprotein B, 1.3  0.3). All were treated only with diet. No
medications were used. A total of 12 blood donors were used as control
subjects (sex [M/F], 6/6; age, 47.8  4.85 years; BMI, 21.25  8.07 kg/m
2;
creatinine, 0.90  0.083 mg/dl; total cholesterol, 164.03  9.68 mmol/l; HDL
cholesterol, 50  8.4 mmol/l; LDL cholesterol, 85.26  16.72 mmol/l; triglyc-
erides, 131.14  25.03 mg/dl; no retinopathy; no hypertension; blood pressure,
126/70 mmHg; cholesterol/apolipoprotein B, 1.6  0.2). Ethics approval was
obtained from both SIMT (Servizio Immunoematologia e Medicina Trasfusio-
nale) and the Institutional Review Board of S. Giovanni Battista Hospital,
Turin, Italy. Informed consent was provided according to the Helsinki
FIG. 1. UAG, by preventing Rac1 activation, protects CACs and EPCs from ROS production. A and B: Dichloroﬂuorescein diacetate assay was
performed on CACs or EPCs, recovered from healthy subjects (nCACs, nEPCs) or from diabetic patients (dCACs, dEPCs) treated with saline,
UAG, or AG (white area: no treatment; dark gray area: UAG infused; light gray area: AG infused). C: CACs and EPCs isolated from healthy
donors (N) and from diabetic patients (D) treated as above were cultured as described in the RESEARCH DESIGN AND METHODS section. Trypan
blue–excluded viable cells were counted (* and § indicate P < 0.05, healthy donors vs. diabetic groups; #P < 0.05, saline vs. UAG infusion). D:
ROS production, in response to apocynin alone or in combination with UAG, was evaluated on dCACs and dEPCs isolated from saline-treated
patients (white area: no treatment; dark gray area: apocynin; light gray area: apocynin  UAG). E: ROS production was evaluated on dCACs
and dEPCs isolated from saline-infused patients and transfected with the scrambled sequence or with p47
phox siRNA. Cells were treated or not
with UAG (white area: scramble; dark gray area: p47
phox siRNA; light gray area: p47
phox siRNA  UAG). F: dCACs and dEPCs retrieved from
saline- or UAG-infused patients were analyzed for Rac1 activation. Cell extracts were either pulled down with GST-PAK or directly subjected to
SDS-PAGE. Eluates or extracts were immunoblotted with an anti-Rac1 antibody. GTP-Rac1 and total Rac1 are indicated. Interleukin-3–treated
endothelial cells were used as positive control (). CACs and EPCs were recovered after a 6-h infusion with saline, UAG, or AG as indicated.
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FIG. 2. UAG prevents dCAC and dEPC senescence. A: Senescence was evaluated on dCACs and dEPCs recovered from saline-infused patients
transfected with pSUPER retro containing p53 siRNA or the scrambled sequence as control and expressed as the percentage of SA--gal–positive
cells (*P < 0.05, scramble vs. p53 siRNA). B: ROS production was evaluated on dCACs and dEPCs recovered from saline-infused patients
transfected with pSUPER retro containing p53 siRNA or the scrambled sequence (white area: scramble; gray area: p53 siRNA). C: dCACs and
dEPCs retrieved from saline- or UAG-infused patients were lysed and analyzed for p53, p21, and pRb expression by Western blotting. Oxidized
LDL–treated endothelial cells were used as positive control (). D: Senescence was evaluated on dCACs and dEPCs recovered from saline- or
UAG-infused patients and expressed as the percentage of SA--gal–positive cells (*P < 0.05, saline vs. UAG infusion).
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subjects.
Testing sessions were as follows: UAG (3.0 g  kg
1  h
1 i.v. as infusion
for 12 h, from 0 to 12 h); AG (1.0 g  kg
1  h
1 i.v. as infusion for 12 h, from
0 to 12 h); and isotonic saline (infusion from 0 to 12 h).
All tests were performed starting at 8:30–9:00 A.M. after overnight fasting.
An indwelling catheter was placed into an forearm vein for slow infusion of
isotonic saline. Cells were isolated from blood samples taken at 0, 6, and 12 h.
Isolation, characterization, and culture of early EPC (CACs) and late
EPCs (EPCs) from peripheral blood mononuclear cells. To isolate CACs,
peripheral blood mononuclear cells retrieved from healthy subjects (nCACs)
or from individuals with type 2 diabetes (dCACs) were plated on ﬁbronectin-
coated dishes as described by Hill et al. (19). Brieﬂy, the cells were cultured
for 4 days in EGM-2 medium (Cambrex, Walkersville, MD). To isolate EPCs
(nEPCs from healthy subjects, dEPCs from individuals with type 2 diabetes),
peripheral blood mononuclear cells were recovered and cultured onto colla-
gen-1–coated dishes for 21 days in EGM-2 medium as described by Yoder et
al. (26). In selected experiments, CACs or EPCs recovered from saline-infused
healthy subjects were cultured with 1.2 mg/ml AGE, H2O2 (100 mol/l), 5
mmol/l glucose, or 25 mmol/l glucose alone or in combination with 1 mol/l
UAG or 1 mol/l AG; 1 mol/l UAG or 1 mol/l AG was also used alone.
Fluorescence-activated cell sorter analysis was used to characterize CAC and
EPC surface markers (anti-CD45, anti-CD14, anti-CD34, anti-CD31, anti–Tie-2,
anti-KDR, anti-vWF antibodies; see supplementary methods, available in an
online appendix at http://diabetes.diabetesjournals.org/cgi/content/full/db09-
0858/DC1). eNOS expression was also evaluated.
Diabetic and control mice. The plasma glucose and insulin determination
for each group of mice (Charles River Lab, Lecco, Italy) are reported: 16
8-week-old ob/ob mice (blood glucose, 296  19.6 mg/dl; insulin, 55  9 ng/ml);
16 8-week-old C57BL/6J wild-type mice (blood glucose, 92  7.2 mg/dl; insulin,
10  0.5 ng/ml). Animal procedures conformed to the Guide for the Care and
Use of Laboratory Animals (27). Blood glucose was measured with a One
Touch II glucose meter (LifeScan, Mountain View, CA). Serum insulin was
measured with a mouse insulin radioimmunoassay kit (Linco Research, St.
Charles, MO), following the manufacturer’s instructions.
Reagents and antibodies. All reagents and antibodies used are reported in
the supplementary methods.
Detection of ROS; GTP-Rac1 loading assay; senescence assay; Western blot
analysis; silencing of endogenous p53, Akt, and p47
phox by small interfering
RNAs (siRNAs); Matrigel plug assay; immunohistochemistry and immu-
noﬂuorescence; human and mouse mobilization assays; enzyme-linked immu-
nosorbent assay and radioimmunoassay; isolation and culture of bone
marrow–derived cells; and evaluation of MMP9 activation, cytoﬂuorimetry
analysis, and in vitro migration assays were described in detail in the
supplementary methods.
Statistical analysis. In vitro and in vivo results are representative of at
least three independent experiments, performed at least in triplicate. Densi-
tometric analysis using a Bio-Rad GS 250 molecular imager was used to
calculate the differences in the fold induction of protein activation or
expression. Signiﬁcance of differences between experimental and control
values (*, #, °, and § indicate P  0.05, statistically signiﬁcant) was calculated
using ANOVA with Newman-Keuls multicomparison test.
RESULTS
UAG protects diabetic EPCs from oxidative stress by
regulating Rac1. Several lines of evidence indicate that
the number and function of EPCs are impaired in diabetes
(17,19) and that these events rely mainly on Nox-mediated
ROS production (15). The effect of in vivo UAG and AG
administration in protecting both CACs and EPCs from
oxidative damage was ﬁrst evaluated. Toward this end,
cells isolated from UAG- or AG-treated individuals with
type 2 diabetes and healthy subjects were characterized
for CAC and EPC markers (supplementary Fig. 1) (18) and
subjected to dichloroﬂuorescein diacetate ﬂuorescence
assay. The results reported in Fig. 1A and B demonstrate
that UAG, but not AG, treatment (6 h) drastically reduced
ROS production in individuals with type 2 diabetes. More-
over, the number of viable cells was signiﬁcantly higher
after UAG treatment compared with before (Fig. 1C). A
protective effect of UAG on ROS production was also
demonstrated in cells cultured with AGE or high glucose
(supplementary Fig. 2A). Similar results were obtained
when H2O2 was used (supplementary Fig. 2B). These
ﬁndings, together with the observation that neither in vitro
nor in vivo UAG administration (supplementary Fig. 2C
and D) changed AGE receptor (RAGE) expression, sug-
gest that effector(s) downstream of RAGE is the target for
protective effect of UAG. Because similar results were
obtained after 12 h of treatment (data not shown), data
throughout the study relates to 6-h UAG treatment.
Apocynin, known to affect the assembly of Nox subunits
(28), was used to investigate the role of Nox in regulating
ROS production. Cells recovered from saline-infused indi-
viduals with type 2 diabetes were subjected to apocynin
treatment. ROS production was prevented in both dCACs
and dEPCs (Fig. 1D). UAG addition could not further
enhance apocynin’s effects (Fig. 1D), suggesting that Nox
activity might be controlled by UAG. As the assembly of
p47
phox and p67
phox subunits is required for Nox enzymatic
activity (29), silencing of p47
phox in dCACs and dEPCs
(supplementary Fig. 3A) prevented ROS production (Fig.
1E). Once more, this effect could not be further enhanced
by the addition of UAG (Fig. 1E). Nox2 activity is also
dependent on the small GTPase Rac (29). ROS generation
in response to AGE (supplementary Fig. 3B and C)w a s
prevented in cells expressing a dominant-negative RacN17
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FIG. 3. UAG increases de novo vessel formation. A: Immunohistochem-
istry of representative functional vessels formed by labeled dCACs and
dEPCs, recovered from saline-infused (left) or from UAG-infused
(right) diabetic patients. Black arrows indicate labeled cells (40
magniﬁcation). B: Quantiﬁcation of newly formed vessels was ex-
pressed as percentage  SD of the vessel area to the total Matrigel area
(*P < 0.05, saline infused vs. UAG infused). (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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Rac1 activity. Indeed, Rac1 activation was detected in cells
recovered from saline-treated individuals with type 2
diabetes, but not from UAG-infused patients (Fig. 1F).
Similar results were obtained in vitro by culturing cells
with AGE (supplementary Fig. 3D). Hence, the modulation
of Rac1 activity is a crucial step in the UAG anti-ROS
protective effect.
Rac1 membrane localization and function rely on
isoprenylation, which has been correlated with AMP-
activated protein kinase (AMPK)-dependent hydroxy-
methylglutaryl CoA reductase activity (30). To rule out
the possibility that inhibition of Rac1 activity by UAG
depends on this pathway, AMPK phosphorylation was
evaluated. Neither short- nor long-term exposure to
UAG alone or in combination with AGE affected AMPK
activity (supplementary Fig. 4).
UAG prevents cell senescence and improves de novo
vessel formation. p53, p21, and pRb are major regulators
of cell senescence (31). The above results prompted us to
evaluate whether the increase in ROS production, gener-
ally considered as an upstream signal, translates into an
accelerated onset of senescence and whether UAG could
rescue this effect. Because both senescence and ROS
generation (Fig. 2A and B) were prevented by silencing
p53 (supplementary Fig. 5A), we investigated the in vivo
effect of UAG on p53 expression. Accordingly, UAG treat-
ment was able to prevent p53 accumulation, p21 expres-
sion, and Rb phosphorylation (Fig. 2C) and to reduce the
number of senescence-associated -galactosidase (SA--
gal)-positive dCACs and dEPCs (Fig. 2D) in UAG-chal-
lenged patients. Similar results were obtained in AGE-
treated cells (supplementary Fig. 5B and C).
To assess whether the protective effect of UAG also
resulted in an enhancement of dCAC and dEPC vasculo-
genic capability, de novo vessel formation was analyzed in
severe combined immunodeﬁcient mice injected with cells
recovered from UAG-treated individuals with type 2 dia-
betes. At 15 days after injection, plugs were recovered and
analyzed by immunohistochemistry. As shown in Fig. 3A
and B, the number of functional vessels formed by cells
recovered from UAG-treated patients was signiﬁcantly
increased with respect to those from saline-treated pa-
tients. The origin of neovessels from host vasculogenic
cells was excluded because the majority of vessels were
lined by human HLA class I–positive cells (supplementary
Fig. 6) (32). Thus, these data provide evidence that UAG
restores dCAC and dEPC vasculogenic activity.
UAG improves EPC mobilization. Defective EPC and
CAC mobilization has been reported in diabetes (19,20).
To further investigate the potential therapeutic effect of
UAG, CACs and EPCs were recovered from 10 normal
healthy subjects and 10 individuals with type 2 diabetes,
characterized, and counted. UAG treatment led to an
increase in the number of recovered cells in individuals
with type 2 diabetes compared with that of healthy sub-
jects, and no effect of UAG treatment was detected in
healthy subjects (Fig. 4A). In contrast, no differences
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FIG. 4. UAG induces CAC and EPC mobilization. A: Percentage of CACs and EPCs recovered after6ho fsaline, UAG, or AG treatment: (N) healthy
donors and (D) diabetic patients (*P < 0.05, diabetic patients vs. healthy donors, #P < 0.05 saline vs. UAG infusion). B: Senescence was evaluated
on CACs and EPCs recovered as described in A and expressed as the percentage of SA--gal–positive cells (*P < 0.05, diabetic patients vs. healthy
donors, #P < 0.05 saline vs. UAG infusion). C: Percentage of EPCs recovered from wild-type or ob/ob mice infused for 12 h with saline, UAG, or
AG (*P < 0.05 WT UAG-infused vs. ob/ob UAG-infused mice). D: Senescence was evaluated on murine EPCs treated as described in C and
expressed as the percentage of SA--gal–positive cells (*P < 0.05, WT vs. ob/ob mice, #P < 0.05 saline vs. UAG infusion). All data are the mean 
SD obtained by three individual investigators.
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individuals were observed (Fig. 4A). In addition, as shown
in Fig. 4B, the percentage of circulating senescent dCACs
and dEPCs decreased upon UAG treatment.
Circulating stromal derived factor-1 (SDF-1) (33) and
vascular endothelial growth factor (VEGF) (34) strictly
control progenitor cell mobilization under stress condi-
tions. We herein demonstrate that 6- or 12-h (data not
shown) UAG or AG infusion did not change their serum
concentrations (supplementary Fig. 7). Similarly, IGF-1
(35) serum concentration was not affected by UAG treat-
ment (supplementary Fig. 7).
UAG mobilizes EPCs by rescuing eNOS activity. For
validation and characterization of the molecular mecha-
nisms regulating bone marrow mobilization, a mouse
model of type 2 diabetes (ob/ob mice) was used. After
treatment with saline, UAG, or AG, recovered cells were
subjected to ﬂuorescence-activated cell sorter analysis for
surface markers to conﬁrm EPC identity (data not shown).
UAG treatment induced a strong increase of recovered
EPCs only in ob/ob mice (Fig. 4C). Finally, the number of
senescent cells was signiﬁcantly lower in UAG-treated
ob/ob mice compared with untreated or AG-treated
animals (Fig. 4D), reproducing our ﬁndings in human
subjects.
As an impairment of eNOS phosphorylation contributes
to defective EPC mobilization in the diabetic setting (36),
we investigated whether UAG modulated eNOS activity
and the activation of its regulatory protein, Akt (37), in
bone marrow stromal cells. The stromal origin of the
eNOS-expressing cells was conﬁrmed by the presence of
mbKitL (Fig. 5A). In ob/ob mice, UAG treatment restored
both eNOS and Akt phosphorylation (Fig. 5A). Consistent
with the pivotal role of a local activation of MMP9 in
promoting progenitor cell mobilization (22), gelatin zy-
mography revealed that MMP9 gelatinolytic activity was
induced by UAG (Fig. 5B). The role of MMP9 activation
and sKitL release in controlling this event was further
conﬁrmed by functional studies using anti-MMP9 and
anti-KitL neutralizing antibodies (Fig. 5C). Accordingly, in
parallel with effects on MMP9 activation, expression of the
mbKitL was decreased in ob/ob mice subjected to UAG
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gelatinolytic activity on serum recovered from saline- or UAG-treated mice. As positive control, human serum was used (). C: Migration assays
performed on bone marrow cells using sera recovered from saline- or UAG-treated ob/ob mice. MMP9 or sKitL neutralizing antibodies were added
where indicated (*P < 0.05, saline vs. UAG, #P < 0.05, UAG vs. UAG  anti-MMP9 and UAG  anti-sKitL). D: Adherent cells obtained from ob/ob
total bone marrow pools were treated as indicated for 40 min and processed for Western blotting using the indicated antibodies. E: Adherent cells
from ob/ob total bone marrow pools were depleted (siRNA Akt) or not (scrambled) of Akt, subjected to UAG treatment, and analyzed by Western
blotting using the indicated antibodies.
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possibility that a paracrine effect of UAG occurs in vivo,
herein we have shown that in vitro UAG treatment for 40
min elicited Akt and eNOS phosphorylation in stromal
cells obtained from ob/ob-derived total bone marrow pools
(Fig. 5D). In agreement with the results measuring EPC
mobilization, AG failed to induce Akt and eNOS phosphor-
ylation (Fig. 5D). The ﬁnding that UAG failed to induce
eNOS phosphorylation after knocking down Akt (Fig. 5E)
or inhibiting its activation (Akt inhibitor) (Fig. 5D) indi-
cates that Akt is a key modulator of the UAG effect. The
above data were validated by the lack of effect of UAG
treatment in NOS3
/ mice (23) (supplementary Fig. 8).
CACs express speciﬁc UAG-binding sites. Based on
our collective dataset, we further investigated whether the
biological response of CACs to UAG was mediated by
speciﬁc binding sites localized to the plasma membrane.
To this end, double immunoﬂuorescence experiments,
using the UAG analog 488-UAG (100 nmol/l) to label
putative binding sites and anti–phycoerythrin-CD45 anti-
body as a membrane marker, were carried out at 4°C. As
shown in Fig. 6A, at 4°C 488-UAG–binding sites colocal-
ized with CD45, indicating a plasma membrane localiza-
tion. In agreement with the functional data, unlabeled
UAG (1 mol/l) displaced the ﬂuorescent signal from the
cell surface, whereas AG (1 mol/l) did not (Fig. 6A). In
addition, we also monitored receptor activation at 25°C.
As shown in Fig. 6B, after 20-min stimulation, receptor
clusters undergoing internalization were visualized as
labeled cytoplasmic vesicles. Moreover, increasing con-
centrations of unlabeled UAG speciﬁcally displaced the
ﬂuorescent ligand from both the plasma membrane and
endocytic vesicles (Fig. 6C and supplementary Fig. 9).
Similar results were obtained using EPCs (data not
shown).
DISCUSSION
The present data ﬁrst demonstrate that UAG, unlike AG,
reverts diabetes-induced EPC damage by inhibiting activa-
tion of the Nox regulatory protein Rac1; as a consequence,
UAG protects diabetic EPCs from senescence and im-
proves their vasculogenic capability; again, only UAG
rescues EPC mobilization under diabetic conditions by
restoring eNOS phosphorylation, and speciﬁc UAG-bind-
ing sites mediate its effects.
UAG is the most abundant circulating form of ghrelin (3)
and plays a positive role on glucose metabolism. In
contrast, basic and clinical studies have proposed AG as a
diabetogenic hormone (8,38). Indeed, clinical conditions
of insulin resistance are associated with an alteration in
the circulating ghrelin proﬁle with relative AG excess with
respect to UAG (12). Thus, it is tempting to speculate that
an altered UAG/AG ratio might contribute both to meta-
bolic changes and to diabetes-associated complications.
Among diabetes-associated complications, abnormal
vascular remodeling is believed to play a major role in
accelerating vascular disease (39). Historically, it has been
assumed that new blood vessels originate from sprouting
cells and co-opting of neighboring preexisting vessels.
However, both physiological and pathologic angiogenesis
are also supported by mobilization and recruitment of
other cell types, including the bone marrow–derived cells,
such as EPCs (16,18,40,41). Interestingly, alterations in the
number and function of these cells correlate with the risk
factor proﬁle (19,20). Overproduction of ROSs in these
pathologic settings seems to contribute to impaired vas-
cular regenerative processes (42). The plasma membrane
Nox is recognized as one of the major regulators of ROS
generation (15,29). Activation of the enzyme can occur via
many upstream signaling pathways converging on phos-
A
B
CTRL 488-UAG
CTRL 488-UAG
CTRL 488-UAG
UAG
100 nM 10 nM 1 µM
AG 1 µMU A G  1  µM
C
FIG. 6. Visualization of UAG-binding sites on CACs by 488-UAG. A–C: Living cells were incubated in the absence (CTRL) or presence of 100 nmol/l
488-UAG with or without the indicated ligands. The putative receptor is stained in green (488-UAG); the plasma membrane in red
(phycoerythrin-CD45); and the nucleus in blue (DAPI). A: Visualization of 488-UAG–binding site distribution on CAC plasma membrane. CAC
incubation with ligands was carried out at 4°C for 4 h. 488-UAG was displaced by 1 mol/l UAG but not by 1 mol/l AG (40 magniﬁcation). B
and C: Visualization of 488-UAG–binding distribution on CACs upon incubation with the indicated ligands for 20 min at 25°C. B: Representative
photomicrograph showing the 488-UAG–labeled cell surface binding sites internalized into endocytotic vesicles (20 magniﬁcation). C: 488-UAG
binding and internalization were completed by increasing concentrations of the unlabeled UAG. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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phox and activation of Rac1 leading to
the oxidase assembly (29). Our study shows that UAG can
protect diabetic EPCs from oxidative stress by affecting
the Nox regulatory protein Rac1.
The accelerated onset of senescence contributes to the
impaired EPC bioavailability in patients with diabetes
(17). The tumor suppressor p53 is a transcription factor
involved in DNA damage mechanisms and is recognized as
a negative regulator of cell proliferation in human athero-
sclerotic and restenosis lesions (43). Moreover, the p53-
mediated pathway contributes to EPC senescence-like
growth arrest in diabetes (44). Accordingly, the present
study shows that silencing p53 in EPCs isolated from
individuals with type 2 diabetes or cultured with AGE
prevents both ROS production and senescence. The ﬁnd-
ing that both in vitro and in vivo exposure to UAG
negatively modulates p53 accumulation identiﬁes the p53-
mediated signal as the primary mechanism through which
UAG protects EPCs from senescence. We also found that,
by preventing oxidative stress, UAG improves de novo
vessel formation. The efﬁcacy of cell therapy certainly
depends on the number, functional capability, and suc-
cessful retention of cells in the site of action. Thus, our
data strongly suggest that naturally occurring UAG in-
duces improvement of EPC function and survival that may
translate into a more efﬁcient response to vascular
dysfunction.
Senescence is also associated with impaired mobiliza-
tion of bone marrow–derived cells (17). The molecular
interactions between stem cells and bone marrow stromal
cells, and the molecular mechanisms controlling their
mobilization in the bone marrow microenvironment, are
poorly understood (45). Considerable interest has arisen
about agents able to mobilize and augment progenitor cell
delivery to sites of vascular injury to enhance revascular-
ization. Among these, SDF-1 and VEGF are recognized as
primary regulators of bone marrow cell mobilization dur-
ing stress conditions (22,46). In addition, under physiolog-
ical stresses, the activation of matrix proteases within the
bone marrow microenvironment results in the release of
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FIG. 7. Schematic model for UAG impact on EPC physiology. The resident bone marrow pool of early and late EPCs was mobilized into circulation
after UAG-mediated Akt activation in stromal cells, which leads to eNOS phosphorylation and MMP9 activation. In turn, MMP9 activation
switched on the release of sKitL, a determinant for EPC exit into the bloodstream. In addition, UAG treatment restores diabetic viability of EPCs
and increases their vasculogenic capability by preventing ROS generation and its downstream signaling pathway (p53 accumulation, p21
expression, Rb phosphorylation). This effect results from UAG-mediated inhibition of Rac1 activation, a prerequisite for NADPH oxidase
assembly. BM, bone marrow compartment; PC, peripheral compartment.
G. TOGLIATTO AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, APRIL 2010 1023sKitL, which enables endothelial and hematopoietic pro-
genitor cells to transit from the quiescent to the prolifer-
ative niche and facilitates their mobilization into the
circulation (22). The delivery of progenitor cells to sites of
neovascularization also relies on functional eNOS activity
(23). Indeed, in pathologic settings associated with
blunted eNOS activity and reduced systemic NO bioavail-
ability, defective EPC mobilization and impaired vascular
regenerative processes occur (24,25). eNOS activation
through Akt has been reported for AG acting on the
Gq-coupled GHS-R1a in cultured endothelial cells (47). We
herein demonstrate that UAG can restore eNOS activity
via Akt-mediated phosphorylation in a pathologic setting
characterized by impaired eNOS phosphorylation. This
was particularly true in bone marrow stromal cells from
diabetic mice. Such an event was found crucial to EPC
bone marrow mobilization, because UAG had no effect in
eNOS knockout mice. Gu et al. (48) identiﬁed MMP9 as a
major target of NO. We also showed that eNOS phosphor-
ylation, occurring in response to UAG, is associated with
MMP9 activation and possibly with the release of sKitL, as
suggested by the reduced expression of the mbKitL on
stromal cells recovered from UAG-treated mice and by
functional studies. Although we cannot exclude that UAG
may act in a paracrine manner by locally inducing the
release of VEGF from bone marrow stromal cells, we
demonstrate that short-term treatment with UAG, but not
AG, of bone marrow cells in vitro leads to Akt and eNOS
phosphorylation and that, in vivo, these events are
associated with MMP9 activation and EPC mobilization.
Furthermore, UAG, unlike AG, strongly induced EPC
mobilization in individuals with type 2 diabetes, but not
in nondiabetic subjects. Notably, no change in serum
concentrations of primary mobilization factors was de-
tected after UAG or AG systemic administration.
In addition, our results shed light on the earliest molec-
ular events leading to UAG- but not AG-mediated physio-
logical regulation of EPC bioavailability. Indeed, we
showed that EPCs possess speciﬁc UAG-binding sites,
which are not recognized by AG. In addition to GHS-R1a,
which is the AG-speciﬁc receptor (3), other ghrelin recep-
tor subtypes exist, whose molecular identities have not yet
been characterized, but that recognize both AG and UAG
(3). Thus, our data provide the ﬁrst evidence of the
existence of UAG-speciﬁc binding sites and of their rele-
vance in human-derived EPCs, which could represent a
novel target for pharmacological modulation.
Preclinical and clinical studies generally support the
therapeutic potential of autologous EPCs in the treatment
of cardiovascular diseases, such as tissue ischemia and
myocardial infarction (49). However, EPC mobilization
may also accelerate atherosclerotic plaque progression
(50) and induce tumor (51) or retina (52) neovasculariza-
tion in individuals with type 2 diabetes. Nonetheless,
therapies with statins, the main EPC mobilization media-
tors (53), revealed no concerns in terms of neovascular-
ization. We now have reason to believe that the signiﬁcant
EPC mobilization potential of UAG, and the lack of its
effects on serum levels of SDF-1 and VEGF, may be
exploited for clinical treatment of diabetes- and athero-
sclerosis-induced vascular impairment.
In the presence of cardiovascular risk factors such as
diabetes, EPC availability is reduced, restricting the pos-
sibility of treating patients in need with directed/cell-based
therapies. Besides displaying a positive inﬂuence on -cell
viability and glucose homeostasis (3), UAG mobilizes
EPCs, protects EPCs from oxidative stress and from
senescence, and increases de novo vessel formation (see
model in Fig. 7). This suggests that UAG-related peptides
or UAG receptor–speciﬁc agonists may be further devel-
oped into lead compounds from the perspective of a novel
pharmacologic intervention to ameliorate both metabolic
control and impaired vascular growth in individuals with
type 2 diabetes where AG has failed.
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